Paul R. Kirchgraber - 27 Mar 2022 Form 4 Insider Report for LABORATORY CORP OF AMERICA HOLDINGS (LH)

Role: CEO, Covance Drug Development
Signature: /s/ Sandra van der Vaart, Attorney-in-Fact for Paul R. Kirchgraber
Issuer symbol: LH
Transactions as of: 27 Mar 2022
Net transactions value: -$455,540
Form type: 4
Filing time: 29 Mar 2022, 12:04:20 UTC
Previous filing: 15 Feb 2022
Next filing: 03 Nov 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	LH	Common Stock	Award	$0	+3,707	+38%	$0.000000	13,563	27 Mar 2022	Direct	F1
transaction	LH	Common Stock	Tax liability	$455,540	-1,648	-12%	$276.42	11,915	28 Mar 2022	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Shares acquired on March 27, 2022, pursuant to a performance award granted on February 12, 2019, relating to performance during the three-year period ended December 31, 2021.
F2	Stock withholding to satisfy tax withholding obligations.